In a patient with osteoporosis and a prior pelvic fracture who sustained a foot fracture while on alendronate (Fosamax), then received two doses of zoledronic acid (Reclast) and now shows a 5‑5.5% loss of lumbar spine bone mineral density with stable hip BMD and a lowest T‑score of –2.0, what is the next step in management?

Switch to Anabolic Therapy Immediately

This patient has failed sequential antiresorptive therapy with continued BMD loss and fractures, indicating treatment failure—the next step is to switch to an anabolic agent (teriparatide, abaloparatide, or romosozumab) followed by antiresorptive consolidation.

Rationale for Anabolic Therapy

This patient demonstrates clear treatment failure on bisphosphonates:

• Sustained a fracture while on alendronate (treatment failure #1)
• 5.5% BMD loss at the lumbar spine after two doses of zoledronic acid (treatment failure #2)
• History of pelvic fracture indicating high fracture risk
• Current T-score of -2.0 (still osteopenic/osteoporotic range)

The 2020 AACE/ACE guidelines explicitly state that anabolic agents should be considered as initial therapy for patients at very high fracture risk, including those with multiple vertebral fractures, very low T-scores, or fractures while on antiresorptive therapy 1. Your patient fits this profile with fractures occurring despite bisphosphonate treatment.

Why Antiresorptives Have Failed

The continued BMD loss on zoledronic acid (5.5% at spine) is particularly concerning. While zoledronic acid typically increases lumbar spine BMD by 4-7% compared to baseline 2, this patient experienced the opposite response. This suggests:

• Inadequate antiresorptive response to bisphosphonates
• Possible secondary causes of bone loss that need evaluation (vitamin D deficiency, hyperparathyroidism, malabsorption, medications)
• Need for a mechanistically different approach (bone formation rather than just resorption inhibition)

Evidence Supporting Anabolic Therapy

The AACE guidelines emphasize that anabolic agents produce greater BMD increases and fracture reduction than antiresorptives in high-risk patients 1. Specifically:

• Teriparatide produced 7% lumbar spine BMD increase vs. 3.4% with alendronate in glucocorticoid-induced osteoporosis
• Romosozumab showed substantially reduced vertebral and clinical fractures compared to alendronate after 1 year
• Anabolic therapy is particularly important when prior antiresorptive therapy has failed

Critical Workup Before Starting Anabolic Therapy

Before initiating anabolic treatment, evaluate for:

1. Vitamin D level (target >30 ng/mL, ideally >40 ng/mL)
2. Serum calcium and PTH (rule out hyperparathyroidism)
3. 25-OH vitamin D, calcium intake assessment
4. Secondary causes: TSH, celiac screen, serum protein electrophoresis, 24-hour urine calcium
5. Medication review: corticosteroids, PPIs, aromatase inhibitors, anticonvulsants
6. Ensure adequate calcium supplementation (1000-1500 mg daily) and vitamin D (800-1200 IU daily) 2

Specific Anabolic Agent Selection

First-line options (choose based on patient factors):

• Romosozumab: Most potent for spine BMD, given monthly for 12 months, then transition to antiresorptive. Contraindicated if MI or stroke within past year 1
• Teriparatide: Daily subcutaneous injection for up to 24 months, excellent vertebral fracture reduction
• Abaloparatide: Daily subcutaneous injection for 18 months, similar efficacy to teriparatide

Sequential Therapy Strategy

After completing anabolic therapy (12-24 months depending on agent):

1. Mandatory transition to antiresorptive therapy to maintain gains 1
2. Consider denosumab rather than returning to bisphosphonates given prior bisphosphonate failure
3. Denosumab provides more consistent BMD gains across all skeletal sites and may be more effective after anabolic therapy
4. Critical caveat: If denosumab is used, patient must understand lifelong commitment or require multiple zoledronic acid doses upon discontinuation to prevent rebound bone loss 3

Common Pitfalls to Avoid

• Do not continue current antiresorptive therapy—this patient has demonstrated inadequate response
• Do not switch to another bisphosphonate—cross-resistance is likely given failure on both alendronate and zoledronic acid
• Do not use denosumab as next step without anabolic therapy first—while denosumab is potent, anabolic therapy is superior for rebuilding compromised bone architecture 1
• Do not forget to address secondary causes—treatment will continue to fail if underlying contributors aren't corrected
• Do not start anabolic therapy without ensuring adequate vitamin D and calcium—this compromises treatment efficacy

Monitoring Plan

Once on anabolic therapy:

• Repeat DXA at 12-24 months (after completing anabolic course)
• Bone turnover markers (P1NP, CTX) at 3-6 months to confirm response
• Expect lumbar spine BMD increases of 6-13% with anabolic agents
• After transition to antiresorptive consolidation, monitor DXA every 1-2 years

The stable hip BMD is reassuring but doesn't negate the significant spine loss and fracture history. This patient requires the most aggressive bone-building approach available.